Literature DB >> 30940886

Cochrane Corner: Ocriplasmin-why isn't it being used more?

Michael Grinton1, David H Steel2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30940886      PMCID： PMC7005710          DOI： 10.1038/s41433-019-0407-1

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  1 in total

Review 1.  Optimal management of idiopathic macular holes.

Authors:  Haifa A Madi; Ibrahim Masri; David H Steel
Journal:  Clin Ophthalmol       Date:  2016-01-13
  1 in total
  4 in total

Review 1.  The past, present, and future of enzyme-based therapies.

Authors:  Jennifer N Hennigan; Michael D Lynch
Journal:  Drug Discov Today       Date:  2021-09-16       Impact factor: 7.851

2.  Enzymatic vitreolysis using reengineered Vibrio mimicus-derived collagenase.

Authors:  Mithun Santra; Maryada Sharma; Deeksha Katoch; Sahil Jain; Uma Nahar Saikia; Mangat R Dogra; Manni Luthra-Guptasarma
Journal:  Mol Vis       Date:  2021-04-01       Impact factor: 2.367

3.  Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model.

Authors:  Christoph Paul; Hans-Helge Müller; Thomas Raber; Thomas Bertelmann
Journal:  PLoS One       Date:  2022-07-25       Impact factor: 3.752

4.  OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.

Authors:  David H W Steel; Niall Patton; Theodor Stappler; Niral Karia; Hans Hoerauf; Nishal Patel; Joachim Wachtlin; Thomas Raber; Petra Kozma-Wiebe
Journal:  Retina       Date:  2021-02-01       Impact factor: 3.975
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.